A framework for stakeholder engagement in the adoption of new anti-malarial treatments in Africa: a case study of Nigeria

Mokuolu, Olugbenga A.; Bolarinwa, Oladimeji Akeem; Opadiran, Oluwatumobi Racheal; Ameen, Hafsat Abolore; Dhorda, Mehul; Cheah, Phaik Yeong; Amaratunga, Chanaki; Haan, Freek de; Tindana, Paulina; Dondorp, Arjen M.

doi:10.1186/s12936-023-04622-2

Cited by 3 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These stakeholder engagement strategies should be encompassing and should target decision-makers, regulators and supply chain actors. Indeed, it is widely acknowledged that transitioning to new malaria therapies can be a lengthy process [ 18 , 19 ] and that early stakeholder engagement is a driving force towards accelerated uptake of malaria interventions [ 20 , 21 ]. In contrast to Vietnam and Lao PDR, Cambodia is already anticipating the potential introduction of TACT.…”

Section: Discussionmentioning

confidence: 99%

Strategies for deploying triple artemisinin-based combination therapy in the Greater Mekong Subregion

de Haan,

Amaratunga,

Thi

et al. 2023

Malar J

Self Cite

View full text Add to dashboard Cite

Background This is a qualitative study to identify implementation challenges for deploying triple artemisinin-based combination therapy (TACT) in the Greater Mekong Subregion (GMS) of Southeast Asia and to explore strategies to overcome these challenges. Methods In-depth interviews were conducted in three countries that have repeatedly been confronted with ACT failures: Cambodia, Vietnam, and Lao PDR. Thirty-nine key stakeholders in the healthcare systems in these countries were interviewed. One participatory workshop was conducted in Cambodia, where scenarios for potential TACT deployment were discussed. Results The results section is organized around four strategic themes that emerged from the data: policy support, data and evidence, logistics and operation, and downstream engagement. The study revealed that countries in the GMS currently rely on ACT to eliminate Plasmodium falciparum malaria by 2025. TACT is, however, considered to be a useful backup strategy in case of future treatment failures and to prevent the re-establishment of malaria. The study showed that a major challenge ahead is to engage decision makers and healthcare providers into deploying TACT, given the low case incidence of falciparum malaria in the GMS. Interview respondents were also skeptical whether healthcare providers would be willing to engage in new therapies for a disease they hardly encounter anymore. Hence, elaborate information dissemination strategies were considered appropriate and these strategies should especially target village malaria workers. Respondents proposed several regulatory and programmatic strategies to anticipate the formation of TACT markets in the GMS. These strategies include early dossier submission to streamline regulatory procedures, early stakeholder engagement strategies to shorten implementation timelines, and inclusion of TACT as second-line therapy to accelerate their introduction in case they are urgently needed. Conclusions This paper presents a qualitative study to identify implementation challenges for deploying TACT in the GMS and to explore strategies to overcome these challenges. The findings could benefit researchers and decision makers in strategizing towards potential future deployment of TACT in the GMS to combat artemisinin and partner drug resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

Strategies for deploying triple artemisinin-based combination therapy in the Greater Mekong Subregion

de Haan,

Amaratunga,

Thi

et al. 2023

Malar J

Self Cite

View full text Add to dashboard Cite

show abstract

Malaria vaccine efficacy, safety, and community perception in Africa: a scoping review of recent empirical studies

Chutiyami,

Saravanakumar,

Bello

et al. 2024

Infection

View full text Add to dashboard Cite

Aim The review summarizes the recent empirical evidence on the efficacy, safety, and community perception of malaria vaccines in Africa. Methods Academic Search Complete, African Journals Online, CINAHL, Medline, PsychInfo, and two gray literature sources were searched in January 2023, and updated in June 2023. Relevant studies published from 2012 were included. Studies were screened, appraised, and synthesized in line with the review aim. Statistical results are presented as 95% Confidence Intervals and proportions/percentages. Results Sixty-six (N = 66) studies met the inclusion criteria. Of the vaccines identified, overall efficacy at 12 months was highest for the R21 vaccine (N = 3) at 77.0%, compared to the RTS,S vaccine (N = 15) at 55%. The efficacy of other vaccines was BK-SE36 (11.0–50.0%, N = 1), ChAd63/MVA ME-TRAP (− 4.7–19.4%, N = 2), FMP2.1/AS02A (7.6–9.9%, N = 1), GMZ2 (0.6–60.0%, N = 5), PfPZ (20.0–100.0%, N = 5), and PfSPZ-CVac (24.8–33.6%, N = 1). Injection site pain and fever were the most common adverse events (N = 26), while febrile convulsion (N = 8) was the most reported, vaccine-related Serious Adverse Event. Mixed perceptions of malaria vaccines were found in African communities (N = 17); awareness was generally low, ranging from 11% in Tanzania to 60% in Nigeria (N = 9), compared to willingness to accept the vaccines, which varied from 32.3% in Ethiopia to 96% in Sierra Leone (N = 15). Other issues include availability, logistics, and misconceptions. Conclusion Malaria vaccines protect against malaria infection in varying degrees, with severe side effects rarely occurring. Further research is required to improve vaccine efficacy and community involvement is needed to ensure successful widespread use in African communities.

show abstract

Triple artemisinin-based combination therapy (TACT): advancing malaria control and eradication efforts

Kokori,

Olatunji,

Akinboade

et al. 2024

Malar J

View full text Add to dashboard Cite

This paper examines the far-reaching implications of Triple Artemisinin-Based Combination Therapy (TACT) in the global battle against malaria. Artemisinin-Based Combination Therapy (ACT) is recognized for its cost-effectiveness, lower likelihood of adverse events, and widespread acceptance by patients and healthcare providers. However, TACT introduces novel dimensions to the fight against malaria that make them a superior choice in several aspects. TACT has been demonstrated to address resistance, offer a broader spectrum of action, reduce the risk of treatment failure, and can be tailored to meet regional needs, strengthening the global effort to combat malaria. However, maximizing these benefits of TACT depends on accessibility, particularly in resource-limited regions where malaria is most prevalent. Collaborative efforts among stakeholders, sustainable pricing strategies, efficient supply chains, and public–private partnerships are essential to ensure that TACT reaches needy populations. Moreover, dispelling prevalent malaria myths through health education campaigns is critical in this endeavour. The paper underscores the significance of collaborative initiatives and partnerships among governments, international organizations, research institutions, acadaemia, pharmaceutical companies, and local communities. Together, these efforts can pave the way for the acceptance, adoption, and success of TACT, ultimately advancing the global goal of a malaria-free world.

show abstract

A framework for stakeholder engagement in the adoption of new anti-malarial treatments in Africa: a case study of Nigeria

Cited by 3 publications

References 41 publications

Strategies for deploying triple artemisinin-based combination therapy in the Greater Mekong Subregion

Strategies for deploying triple artemisinin-based combination therapy in the Greater Mekong Subregion

Malaria vaccine efficacy, safety, and community perception in Africa: a scoping review of recent empirical studies

Triple artemisinin-based combination therapy (TACT): advancing malaria control and eradication efforts

Contact Info

Product

Resources

About